These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 30288322)

  • 21. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews.
    Nelson PK; Mathers BM; Cowie B; Hagan H; Des Jarlais D; Horyniak D; Degenhardt L
    Lancet; 2011 Aug; 378(9791):571-83. PubMed ID: 21802134
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Public Health Considerations among People who Inject Drugs with HIV/HCV Co-Infection: A Review.
    Murdock RM; Brizzi MB; Perez O; Badowski ME
    Infect Dis Ther; 2019 Mar; 8(1):23-32. PubMed ID: 30607808
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estimating the Consensus hepatitis C Cascade of Care among people who inject drugs in Australia: Pre and post availability of direct acting antiviral therapy.
    Iversen J; Dore GJ; Starr M; Catlett B; Cunningham P; Geddes L; Maher L
    Int J Drug Policy; 2020 Sep; 83():102837. PubMed ID: 32645585
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improved health-related quality of life after hepatitis C viraemic clearance among people who inject drugs may not be durable.
    McDonald SA; Myring G; Palmateer NE; McAuley A; Beer L; Dillon JF; Hollingworth W; Gunson R; Hickman M; Hutchinson SJ
    Addiction; 2023 Jul; 118(7):1340-1350. PubMed ID: 36808787
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intervention Packages to Reduce the Impact of HIV and HCV Infections Among People Who Inject Drugs in Eastern Europe and Central Asia: A Modeling and Cost-effectiveness Study.
    Mabileau G; Scutelniciuc O; Tsereteli M; Konorazov I; Yelizaryeva A; Popovici S; Saifuddin K; Losina E; Manova M; Saldanha V; Malkin JE; Yazdanpanah Y
    Open Forum Infect Dis; 2018 Mar; 5(3):ofy040. PubMed ID: 29594179
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Untreated alcohol use disorder in people who inject drugs (PWID) in France: a major barrier to HCV treatment uptake (the ANRS-FANTASIO study).
    Barré T; Marcellin F; Di Beo V; Delorme J; Rojas Rojas T; Mathurin P; Protopopescu C; Bailly F; Coste M; Authier N; Carrieri MP; Rolland B
    Addiction; 2020 Mar; 115(3):573-582. PubMed ID: 31595554
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Disparities in uptake of direct-acting antiviral therapy for hepatitis C among people who inject drugs in a Canadian setting.
    Socías ME; Ti L; Wood E; Nosova E; Hull M; Hayashi K; Debeck K; Milloy MJ
    Liver Int; 2019 Aug; 39(8):1400-1407. PubMed ID: 30653809
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incidence of primary hepatitis C virus infection among people who inject drugs in Australia pre- and post-unrestricted availability of direct acting antiviral therapies.
    Iversen J; Wand H; McManus H; Dore GJ; Maher L
    Addiction; 2023 May; 118(5):901-911. PubMed ID: 36524842
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epidemiological characteristics and access to end-stage liver disease care for HIV-positive patients with HCV and/or HBV coinfections in Central/Eastern European and neighboring countries – data from the ECEE network.
    Skrzat-Klapaczyńska A; Matłosz B; Otelea D; Harxhi A; Vassilenko A; Bolokadze N; Rüütel K; Papadopoulos A; Mardarescu M; Youle M; Kowalska JD; Horban A
    Przegl Epidemiol; 2019; 73(1):61-68. PubMed ID: 31134775
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The road to elimination of hepatitis C: analysis of cures versus new infections in 91 countries.
    Hill AM; Nath S; Simmons B
    J Virus Erad; 2017 Jul; 3(3):117-123. PubMed ID: 28758018
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modeling indicates efficient vaccine-based interventions for the elimination of hepatitis C virus among persons who inject drugs in metropolitan Chicago.
    Echevarria D; Gutfraind A; Boodram B; Layden J; Ozik J; Page K; Cotler SJ; Major M; Dahari H
    Vaccine; 2019 May; 37(19):2608-2616. PubMed ID: 30962092
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Seroprevalence and burden of hepatitis C virus infection in WHO South-East Asia Region: A systematic review.
    Goel A; Rewari BB; Sharma M; Konath NM; Aggarwal R
    J Gastroenterol Hepatol; 2022 Jun; 37(6):964-972. PubMed ID: 35263807
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 'Treat my whole person, not just my condition': qualitative explorations of hepatitis C care delivery preferences among people who inject drugs.
    Tsui JI; Barry MP; Austin EJ; Sweek EW; Tung E; Hansen RN; Ninburg M; Scott JD; Glick SN; Williams EC
    Addict Sci Clin Pract; 2021 Aug; 16(1):52. PubMed ID: 34384494
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hep-CORE: a cross-sectional study of the viral hepatitis policy environment reported by patient groups in 25 European countries in 2016 and 2017.
    Lazarus JV; Stumo SR; Harris M; Hendrickx G; Hetherington KL; Maticic M; Jauffret-Roustide M; Tallada J; Simojoki K; Reic T; Safreed-Harmon K;
    J Int AIDS Soc; 2018 Apr; 21 Suppl 2(Suppl Suppl 2):e25052. PubMed ID: 29633562
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Injecting drug use: A vector for the introduction of new hepatitis C virus genotypes.
    Ruta S; Cernescu C
    World J Gastroenterol; 2015 Oct; 21(38):10811-23. PubMed ID: 26478672
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Change in treatment paradigm in people who previously injected drugs with chronic hepatitis C in the era of direct-acting antiviral therapy.
    Wong GL; Chan HL; Loo CK; Hui YT; Fung JY; Cheung D; Chung C; Chim AM; Wong VW;
    J Gastroenterol Hepatol; 2019 Sep; 34(9):1641-1647. PubMed ID: 30707777
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The hepatitis C treatment revolution: how to avoid Asia missing out.
    Walsh N; Durier N; Khwairakpam G; Sohn AH; Lo YR
    J Virus Erad; 2015 Oct; 1(4):272-5. PubMed ID: 27482424
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HIV/tuberculosis/hepatitis C virus services for incarcerated populations in Azerbaijan and the Eastern Europe Central Asia region.
    Mehdiyev R; Alikhanova N; Gurbanova E
    Curr Opin HIV AIDS; 2019 Jan; 14(1):66-70. PubMed ID: 30489347
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatitis C treatment uptake among patients who have received methadone substitution treatment in the Republic of Georgia.
    Stvilia K; Vephkvadze N; Gamkrelidze A; Khonelidze I; Getia V; Tsereteli M; Gvinjilia L; Kuchuloria T
    Public Health; 2021 Jun; 195():42-50. PubMed ID: 34051674
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of direct and indirect social and spatial ties in the diffusion of HIV and HCV among people who inject drugs: a cross-sectional community-based network analysis in New Delhi, India.
    Clipman SJ; Mehta SH; Srikrishnan AK; Zook KJ; Duggal P; Mohapatra S; Shanmugam S; Nandagopal P; Kumar MS; Ogburn E; Lucas GM; Latkin CA; Solomon SS
    Elife; 2021 Aug; 10():. PubMed ID: 34342266
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.